Researchers are developing a male birth control injection that will provide long-acting reversible contraception - and it is expected to be available as early as 2017.
The injection, containing a substance called Vasalgel, temporarily blocks the tubes which transport sperm from the testes. In essence it acts in the same way as a vasectomy but it is not permanent.
According to its creators, the Parsemus Foundation in US, the contraceptive has been tested on baboons and rabbits, 'metro.Co.Uk' reported.
The three male baboons were moved into enclosures with 10-15 females a month ago. None of the female baboons were found to be pregnant.
Researchers are now planning to flush out the Vasalgel to check whether sperm starts to flow once again.
In another baboon study, five males have received Vasalgel. The baboons will soon be moved to breeding enclosures with fertile females.
Half of the baboons will be able to mate with females for three months, and half of them will be with females for six months. After this, they will all undergo reversal and additional testing.
The researchers are planning clinical trials with humans next year.
The injection, containing a substance called Vasalgel, temporarily blocks the tubes which transport sperm from the testes. In essence it acts in the same way as a vasectomy but it is not permanent.
According to its creators, the Parsemus Foundation in US, the contraceptive has been tested on baboons and rabbits, 'metro.Co.Uk' reported.
Also Read
Six months ago, researchers injected Vasalgel into three male baboons. The males were then given an opportunity to mate with females.
The three male baboons were moved into enclosures with 10-15 females a month ago. None of the female baboons were found to be pregnant.
Researchers are now planning to flush out the Vasalgel to check whether sperm starts to flow once again.
In another baboon study, five males have received Vasalgel. The baboons will soon be moved to breeding enclosures with fertile females.
Half of the baboons will be able to mate with females for three months, and half of them will be with females for six months. After this, they will all undergo reversal and additional testing.
The researchers are planning clinical trials with humans next year.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%